



# Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent *Clostridioides difficile* Infection

Sahil Khanna<sup>1</sup> · Maha Assi<sup>2</sup> · Christine Lee<sup>3</sup> · David Yoho<sup>4</sup> · Thomas Louie<sup>5</sup> · Whitfield Knapple<sup>6</sup> · Humberto Aguilar<sup>7</sup> · Julia Garcia-Diaz<sup>8</sup> · Gary P. Wang<sup>9</sup> · Scott M. Berry<sup>10</sup> · Joe Marion<sup>10</sup> · Xin Su<sup>11</sup> · Tricia Braun<sup>11</sup> · Lindy Bancke<sup>12</sup> · Paul Feuerstadt<sup>13,14</sup>

Published online: 7 November 2022  
© The Author(s) 2022

## Correction to: Drugs

<https://doi.org/10.1007/s40265-022-01797-x>

An error was introduced by the publisher during the typesetting process.

Table 3 ‘Summary of AEs over the full study period (PUNCH CD3 safety population;  $N = 267$ )’

Second column heading, which currently reads ‘Blinded Placebo ( $n = 870$ )’

Should read:

‘Blinded Placebo ( $n = 87$ )’

The original article has been corrected.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40265-022-01797-x>.

✉ Sahil Khanna  
Khanna.Sahil@mayo.edu

<sup>1</sup> Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA

<sup>2</sup> University of Kansas School of Medicine-Wichita, Wichita, KS, USA

<sup>3</sup> University of Victoria, Victoria, BC, Canada

<sup>4</sup> Kaiser Permanente Springfield Medical Center, Springfield, VA, USA

<sup>5</sup> University of Calgary, Calgary, AB, Canada

<sup>6</sup> Arkansas Gastroenterology, North Little Rock, AR, USA

<sup>7</sup> Louisiana Research Center, Shreveport, LA, USA

<sup>8</sup> Ochsner Clinic, New Orleans, LA, USA

<sup>9</sup> University of Florida, Gainesville, FL, USA

<sup>10</sup> Berry Consultants, LLC, Austin, TX, USA

<sup>11</sup> Formerly of Rebiotix, Inc, Roseville, MN, USA

<sup>12</sup> Rebiotix, Inc, Roseville, MN, USA

<sup>13</sup> Yale School of Medicine, New Haven, CT, USA

<sup>14</sup> PACT Gastroenterology Center, Hamden, CT, USA